TRENTON, N.J. – Drugmaker Merck & Co. said Thursday it is shutting down eight manufacturing plants and eight research sites around the world, including two domestic locations, in the latest phase in its strategic pruning of excess capacity.
The moves will include consolidating some small offices into larger facilities with multiple functions.
The announcement is part of ongoing restructuring following Merck’s acquisition of Schering-Plough Corp. last November.
Late Thursday, the company said in a regulatory filing that it also plans to eliminate 2,500 vacant positions, mainly duplicative positions in sales, administrative and headquarters organizations, as well as some from the 16 sites being sold or closed.
Send questions/comments to the editors.
Success. Please wait for the page to reload. If the page does not reload within 5 seconds, please refresh the page.
Enter your email and password to access comments.
Hi, to comment on stories you must . This profile is in addition to your subscription and website login.
Already have a commenting profile? .
Invalid username/password.
Please check your email to confirm and complete your registration.
Only subscribers are eligible to post comments. Please subscribe or login first for digital access. Here’s why.
Use the form below to reset your password. When you've submitted your account email, we will send an email with a reset code.